Cynata Therapeutics (ASX:CYP) EBIT per Share : A$-0.10 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics EBIT per Share?

Cynata Therapeutics's EBIT per Share for the six months ended in Dec. 2023 was A$-0.04. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.10.

During the past 3 years, the average EBIT per Share Growth Rate was -4.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was -6.50% per year. During the past 10 years, the average EBIT per Share Growth Rate was -7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cynata Therapeutics's EBIT per Share or its related term are showing as below:

ASX:CYP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -33.2 Med: 1 Max: 59.8
Current: -4.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cynata Therapeutics was 59.80% per year. The lowest was -33.20% per year. And the median was 1.00% per year.

ASX:CYP's 3-Year EBIT Growth Rate is ranked worse than
59.54% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs ASX:CYP: -4.50

Cynata Therapeutics's EBIT for the six months ended in Dec. 2023 was A$-7.09 Mil.

Cynata Therapeutics EBIT per Share Historical Data

The historical data trend for Cynata Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics EBIT per Share Chart

Cynata Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT per Share

Get a 7-Day Free Trial

-0.10

-0.07

-0.10

-0.11

Cynata Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.06	-0.04	-0.05	-0.07	-0.04

Cynata Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cynata Therapeutics's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-16.543	/	145.092
=	-0.11

Cynata Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.087	/	179.491
=	-0.04

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.10

Cynata Therapeutics (ASX:CYP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cynata Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics (ASX:CYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

51S:Germany

Address

100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121

Website

https://www.cynata.com

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines